S&P 500   2,877.52 (-3.40%)
DOW   24,817.52 (-3.68%)
QQQ   200.24 (-2.63%)
AAPL   261.16 (-4.52%)
FB   187.02 (-1.44%)
MSFT   156.88 (-0.82%)
GOOGL   1,278.85 (-2.75%)
NVDA   254.17 (+0.62%)
MU   49.89 (-1.36%)
TSLA   624.80 (-7.98%)
AMD   42.80 (-2.75%)
T   34.06 (-4.67%)
F   6.72 (-3.59%)
NFLX   361.84 (-2.66%)
BAC   27.90 (-4.22%)
GILD   66.98 (-7.82%)
DIS   114.02 (-3.41%)
S&P 500   2,877.52 (-3.40%)
DOW   24,817.52 (-3.68%)
QQQ   200.24 (-2.63%)
AAPL   261.16 (-4.52%)
FB   187.02 (-1.44%)
MSFT   156.88 (-0.82%)
GOOGL   1,278.85 (-2.75%)
NVDA   254.17 (+0.62%)
MU   49.89 (-1.36%)
TSLA   624.80 (-7.98%)
AMD   42.80 (-2.75%)
T   34.06 (-4.67%)
F   6.72 (-3.59%)
NFLX   361.84 (-2.66%)
BAC   27.90 (-4.22%)
GILD   66.98 (-7.82%)
DIS   114.02 (-3.41%)
S&P 500   2,877.52 (-3.40%)
DOW   24,817.52 (-3.68%)
QQQ   200.24 (-2.63%)
AAPL   261.16 (-4.52%)
FB   187.02 (-1.44%)
MSFT   156.88 (-0.82%)
GOOGL   1,278.85 (-2.75%)
NVDA   254.17 (+0.62%)
MU   49.89 (-1.36%)
TSLA   624.80 (-7.98%)
AMD   42.80 (-2.75%)
T   34.06 (-4.67%)
F   6.72 (-3.59%)
NFLX   361.84 (-2.66%)
BAC   27.90 (-4.22%)
GILD   66.98 (-7.82%)
DIS   114.02 (-3.41%)
S&P 500   2,877.52 (-3.40%)
DOW   24,817.52 (-3.68%)
QQQ   200.24 (-2.63%)
AAPL   261.16 (-4.52%)
FB   187.02 (-1.44%)
MSFT   156.88 (-0.82%)
GOOGL   1,278.85 (-2.75%)
NVDA   254.17 (+0.62%)
MU   49.89 (-1.36%)
TSLA   624.80 (-7.98%)
AMD   42.80 (-2.75%)
T   34.06 (-4.67%)
F   6.72 (-3.59%)
NFLX   361.84 (-2.66%)
BAC   27.90 (-4.22%)
GILD   66.98 (-7.82%)
DIS   114.02 (-3.41%)
Log in

NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

$2.55
+0.15 (+6.25 %)
(As of 02/28/2020 10:30 AM ET)
Today's Range
$2.29
Now: $2.55
$2.75
50-Day Range
$2.40
MA: $2.88
$3.31
52-Week Range
$2.40
Now: $2.55
$11.36
Volume43,158 shs
Average Volume1.65 million shs
Market Capitalization$288.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$2.65 per share

Profitability

Net Income$-120,010,000.00

Miscellaneous

Employees235
Market Cap$288.07 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.02. The company's revenue for the quarter was up NaN% on a year-over-year basis. During the same quarter last year, the company posted ($0.30) EPS. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

5 Wall Street analysts have issued twelve-month target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $21.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $13.20 in the next year. This suggests a possible upside of 417.6% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News coverage about SPPI stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Spectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 10,250,000 shares, a decline of 21.5% from the January 30th total of 13,050,000 shares. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is currently 4.1 days. Currently, 10.4% of the company's shares are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Verastem (VSTM), Bausch Health Companies (BHC) and AT&T (T).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), Geode Capital Management LLC (1.36%), FMR LLC (1.23%), Bank of New York Mellon Corp (1.12%) and ArrowMark Colorado Holdings LLC (0.95%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., UBS Group AG and Arizona State Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Geode Capital Management LLC, Bank of New York Mellon Corp and Teza Capital Management LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $2.55.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $288.07 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  447 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel